Migraine, which afflicts approximately 34 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s symptoms and needs, headache pattern, comorbidities, contraindications, and treatment history. With the launch of newer migraine-specific treatment alternatives (e.g., anti-CGRP MAbs for migraine prevention, gepants for the treatment of acute migraine attacks) and more on the near-term horizon, brand choice is rapidly expanding in this heavily generic market. Understanding the intersecting forces of unmet need, cost / coverage, and the availability of many low-cost, early-line SOCs will be key to the success of current and future players in migraine.
Questions Answered:
What events will shape the future of the acute and preventive market segments?
How will the anti-CGRP MAbs and gepants impact the migraine prophylaxis market? Which brands will be the most competitive and why?
What is the dynamic between Reyvow, Ubrelvy, and Nurtec ODT? How have they been integrated into the triptan-dominant acute segment?
How will novel reformulations compete for patient share with existing options in the niche segment of patients who need non-oral alternatives?
Product Description:
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement:
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.